ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Evrysdi from ROCHE gets EC nod as home treatment for spinal muscular atrophy
March 31, 2021Roche announced that the European Commission (EC) has approved Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to ... -
Evrysdi Trial Demonstrates Improvement of Motor Function in SMA Patients
March 22, 2021PTC Therapeutics announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam) in children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) at the 2021 Muscular Dystrophy Association (MDA) Virtual and ...
Pharma Sources Insight January 2025
